NYSE: GSKGsk PLC Stock
$46.86-0.08 (-0.17%)
Updated Oct 31, 2025
GSK Price
$46.86
Fair Value Price
N/A
Market Cap
$94.52B
52 Week Low
$31.72
52 Week High
$47.16
P/E
12.99x
P/B
4.39x
P/S
2.02x
PEG
N/A
Dividend Yield
3.51%
Revenue
$42.89B
Earnings
$7.42B
Gross Margin
72.3%
Operating Margin
22.17%
Profit Margin
17.1%
Debt to Equity
2.82
Operating Cash Flow
$11B
Beta
0.36
Next Earnings
N/A
Ex-Dividend
Nov 14, 2025
Next Dividend
Jan 8, 2026
GSK Overview
GSK plc is a pharmaceutical company operating in several therapeutic classes, including respiratory, oncology, and antiviral. It also offers vaccines and consumer healthcare products. Known as GlaxoSmithKline plc until 2022, the company was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. It is headquartered in London, UK.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GSK's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
GSK
Ranked#1 of 19
Ranked#1 of 19
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $862.86 | A | |
| $16.29 | A | |
| $9.37 | B |
Be the first to know about important GSK news, forecast changes, insider trades & much more!
GSK News
Overview
Due Diligence Score
–
Industry Average (39)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GSK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GSK is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GSK is good value based on its earnings relative to its share price (12.99x), compared to the US market average (41.55x)
P/E vs Market Valuation
GSK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more GSK due diligence checks available for Premium users.
Valuation
GSK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
12.99x
Industry
35.14x
Market
41.55x
GSK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GSK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
GSK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.39x
Industry
6.26x
GSK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GSK's financial health
Profit margin
Revenue
$11.6B
Net Income
$2.7B
Profit Margin
23.6%
GSK's Earnings (EBIT) of $9.51B... subscribe to Premium to read more.
Interest Coverage Financials
GSK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$82.9B
Liabilities
$61.6B
Debt to equity
2.82
GSK's short-term liabilities ($28.45B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GSK's long-term liabilities ($32.34B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GSK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GSK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.0B
Investing
-$2.1B
Financing
-$1.8B
GSK's operating cash flow ($10.39B)... subscribe to Premium to read more.
Debt Coverage Financials
GSK vs General Drug Manufacturer Stocks
Gsk Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.